5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8 Puritas >99.0%

Description:

5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine

CAS: 733039-20-8

Puritas: >99.0% (HPLC)

Aspectus: Alba ad Off-White pulveris

Medium Palbociclib (CAS: 571190-30-2)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Palbociclib Intermedia:
Palbociclib CAS 571190-30-2
5-Bromo-2,4-Dichloropyrimidines CAS 36082-50-5
5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8
tert-Butyl 4-(6-Nitropyridin-3-yl) piperazine-1-Carboxylate CAS 571189-16-7
tert-Butyl 4-(6-Amino-3-pyridyl) piperazine-1-Carboxylate CAS 571188-59-5
6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2
2-Chloro-8-Cyclopentyl-5-Methyl-8H-pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4

Chemical Properties:

Nomen chemicum	5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine
Synonyma	N-(5-Bromo-2-Chloropyrimidin-4-yl)(cyclopentyl)amine;5-Bromo-2-Chloro-4-(Cyclopentylamino)pyrimidine
CAS Number	733039-20-8
CATTUS Number	RF-PI1851
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C9H11BrClN3
M. Pondus	276.56
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad Off-White pulveris
Puritas / Analysis Methodus	>99.0% (HPLC)
1 H NMR Spectrum	Congruunt cum Structure
Damnum in Siccatio	<1.00%
Totalis immunditias	<1.00%
Test Standard	Enterprise Standard
Consuetudinem	Medium Palbociclib (CAS: 571190-30-2)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine (CAS: 733039-20-8) adhiberi potest ut medius Palbociclib (CAS: 571190-30-2).Palbociclib (nomen artis: Ibrance)inhibitor selectivus cyclini-dependens kinases CDK4 et CDK6.Palbociclib inhibitor kinasus indicatus est pro curatione hormonum receptoris (HR) - positivae, hominis epidermalis aucti receptoris 2 (HER2) - negativa provecta vel metastatica cancer pectoris in compositione cum: Inhibitor aromatasis endocrinarum initialis fundatae therapiae in mulieribus postmenopausalibus;vel in foeminis cum processu morborum endocrinarum therapiae.